Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE
Summary: Screening initiatives for osteoporosis must facilitate treatment of those at elevated fracture risk. In a randomized controlled trial of 24,229 women, those in the screening group with FRAX ≥ 15% were invited for DXA with AOM treatment offered as per national guidelines. Treatment initiation in the following year was 9.5 times higher compared with controls. Purpose: To determine if screen
